Heading for remission and its continuation in rheumatoid arthritis
The management of rheumatoid arthritis has seen tremendous changes over the past 25 years, since the increasing availability of biological disease-modifying antirheumatic drugs (DMARDs) with various modes of actions and in more recent years targeted synthetic DMARDs. However, of paramount importance was the recommendation on treat-to-target,1 which has meanwhile been imprinted into the mindset of the majority of rheumatologists. The success of treat-to-target steered therapy resulted in elevated remission rates, albeit with variations in the criteria for defining targets, as diverse interpretations of remission status are frequently used in clinical research.
